Written and maintained by CASRAI Editorial Board
Published · Last updated
On this page
General product information only, drawn from the manufacturer’s instructions for use. It is not medical advice and does not describe clinical technique. Always follow the current instructions for use supplied with the product.
Short answer
TheraSkin is a cryopreserved human skin allograft made by LifeNet Health. Its instructions for use (IFU) describe it as processed from donated human skin, disinfected with an antibiotic regimen, cryogenically preserved, and restricted by US federal law to use by a licensed clinician. It is a tissue product that has to be kept frozen and tracked to the recipient, not a conventional wound dressing.
Definition and scope
According to the manufacturer’s product specifications page, TheraSkin is an all-human, split-thickness skin allograft that retains living cells, endogenous growth factors and native extracellular matrix, and is described as a barrier membrane for chronic wounds. The IFU (document 63-0402.04) labels it an “allograft bio-implant” and states that it is processed from donated human skin under aseptic conditions.
The IFU lists the following wound types under its indication for the repair of damaged human skin: diabetic foot ulcers, venous leg ulcers, arterial leg wounds, pressure ulcers, surgical wounds (including Mohs), dehisced surgical wounds, necrotizing fasciitis, traumatic wounds, burns, radiation burns and other chronic skin wounds. Whether a given patient is suitable for the product is a decision for the responsible clinician, not for this page.
How it is handled in practice
The IFU places several responsibilities on the distributor, intermediary or end-user facility rather than on the clinician at the bedside alone. These are the points that matter for staff who receive, store or document the product:
- Storage is the facility’s responsibility. The IFU states that the distributor, intermediary and/or end-user clinician or facility must store TheraSkin as specified before further distribution or application.
- Single use, single patient. Once opened, the graft must be used or discarded, it must not be sterilised, and it must not be refrozen after thawing has begun.
- Inspection on receipt. The IFU directs users to inspect for expiry, damage and label discrepancies.
- Traceability. The end-user is responsible for maintaining recipient records, and a Graft Implant Tracking Card is enclosed to support post-implantation tracking.
- Adverse events and complaints. The IFU directs these to LifeNet Health Client Services, which it lists as available 24 hours a day.
Storage and traceability checklist from the IFU
| Item | What the IFU states |
|---|---|
| Preservation method | Cryopreserved |
| Storage temperature | Frozen at -40 °C to -80 °C (an ultra-low temperature freezer) |
| Shelf life | 5 years from the date of manufacture |
| Do not store in | A liquid nitrogen freezer or a refrigerator |
| Conventional freezer | Permitted at a maximum of -15 °C for up to 12 months, after which the product is no longer eligible to be returned |
| Shipping | Delivered in a thermal container with dry ice |
| After thawing begins | Do not refreeze; use or discard once opened |
| Records | Recipient records kept by the end-user, with the enclosed Graft Implant Tracking Card |
The practical point for receiving and pharmacy or materials-management staff is that the conventional-freezer allowance is a time-limited exception that also forfeits return eligibility, so the date a unit moves out of ultra-low storage is itself a fact worth recording. That reading is an editorial interpretation of the IFU table, not a statement the manufacturer makes in those words. Because the IFU itself notes the potential for transmission of infectious agents, the wider infection-control context is covered in the surgical site infection guide.
Regulatory frame stated in the IFU
The IFU states that tissues are recovered, processed, stored, tested and distributed in accordance with 21 CFR Part 1271 (the FDA regulations for human cells, tissues, and cellular and tissue-based products) and with the Standards for Tissue Banking of the American Association of Tissue Banks (AATB), and that donor suitability is determined by the LifeNet Health physician medical director. The IFU also states that, as with any allograft, the potential for transmission of infectious agents exists, and it lists a contraindication for known or suspected allergy to the antibiotics or processing reagents named in the insert. Residuals the IFU says may be present include gentamicin and/or vancomycin, alcohol, chlorhexidine and a cryosolution of culture medium and glycerol; it states the product is processed without beta-lactam antibiotics.
The regulation itself is published at 21 CFR 1271.10, which sets out the criteria under which an HCT/P is regulated solely under section 361 of the Public Health Service Act. This page does not state which regulatory pathway applies to TheraSkin; the IFU cites Part 1271 for tissue handling, and any pathway question should be answered from FDA or the manufacturer.
Related concepts
TheraSkin is often searched alongside other products used on wounds, so the vocabulary is worth separating. A wound dressing is a covering applied to a wound; the IFU describes TheraSkin as an implant tissue. A dermal matrix is a related category of material used in reconstruction, covered in its own guide. Amniotic membrane products are a different tissue source; TheraSkin is processed from donated skin, not from amniotic tissue. For a pocket overview of wound-care terms, see the wound care pocket guide.
Where it matters for labs, clinics and supply decisions
- Cold-chain equipment. A site that holds the product needs storage that meets the -40 °C to -80 °C range; the IFU names refrigerators and liquid nitrogen freezers as unacceptable.
- Documentation. Because the end-user maintains recipient records, receiving and clinical records need a route to link a lot to a patient.
- Clinician-only restriction. The label restricts use to a licensed clinician, so it is not a general-stock consumable.
- Research and trial supply. Staff handling tissue products for a study should rely on the study protocol and the current IFU for conditions, rather than on a general explainer.
Common misunderstandings
Is TheraSkin an amniotic product?
No. The IFU states that it is processed from donated human skin.
Is it a dressing you can stock like gauze?
No. It is a cryopreserved allograft with a clinician-only restriction, ultra-low-temperature storage, single-use handling and recipient tracking.
Does the 5-year shelf life apply to any freezer?
No. The 5-year figure applies to storage at -40 °C to -80 °C. The IFU allows a conventional freezer (maximum -15 °C) for up to 12 months only.
FAQ
What is TheraSkin?
A cryopreserved human skin allograft from LifeNet Health, described as a split-thickness skin allograft with living cells for chronic wounds.
How is TheraSkin stored?
Frozen at -40 °C to -80 °C, with a 5-year shelf life from manufacture; not in liquid nitrogen or a refrigerator. A conventional freezer is allowed for up to 12 months.
Can anyone use it?
The IFU states that federal law restricts it to use by a licensed clinician.
Where do adverse events go?
The IFU directs complaints and adverse events to LifeNet Health Client Services.
Sources
- LifeNet Health, TheraSkin Instructions for Use, document 63-0402.04, read 2026-11-08.
- LifeNet Health, TheraSkin product specifications, read 2026-11-08.
- Legal Information Institute, 21 CFR 1271.10, read 2026-11-08.







